Đang chuẩn bị liên kết để tải về tài liệu:
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAFV600 kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. | Vemurafenib in Chinese patients with BRAFV600 mutation positive unresectable or metastatic melanoma An open-label multicenter phase I study

TÀI LIỆU LIÊN QUAN

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

Báo cáo sinh học: "Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations"

báo cáo hóa học:" Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations"

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Case series: Indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma

Safety and efficacy of vemurafenib in end stage renal failure

An effective treatment in Erdheim Chester disease: Vemurafenib: A case report